NCT06232902View on ClinicalTrials.gov

A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

November 18, 2024

Study Completion Date

November 18, 2024

Conditions
Tumor
Interventions
DRUG

QL1101

3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day

DRUG

Avastin®

3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day

Trial Locations (1)

130000

The First Affiliated Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT06232902 - A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers | Biotech Hunter | Biotech Hunter